Vincenzo Bronte, M.D.
Professor, University of Verona, Department of Medicine
Vincenzo Bronte, M.D., is currently head of the immunology section in the Department of Medicine of Verona University and head of the diagnostic immunology unit in the “G. B. Rossi” Hospital. He is full professor of immunology at the University of Verona. He has mentored over 30 students and post-docs.
Dr. Bronte was awarded by the Accademia Nazionale dei Lincei (Rome, Italy) with the International Prize “Francesco De Luca” for a scientific oncology career, and the Prize “Guido Venosta” for oncology researchers by the Italian Foundation for Cancer Research (FIRC).
Dr. Bronte’s major achievements have been the definition and characterization of immune regulatory cells, now called myeloid-derived suppressor cells (MDSCs). The negative influence of these cells on antitumor immunity represents an obstacle to a successful immunotherapy of cancer. Current projects are further exploring the cellular and molecular mechanisms underlying tumor-induced immune dysfunctions, with the attempt to define novel drugs and approaches targeting the tumor microenvironment to be used alone or in combination with either active or passive immunotherapy strategies.
Dr. Bronte has been invited several times to Society for Immunotherapy of Cancer’s (SITC) Annual Meeting as speaker, chairman and teacher for the educational “Primer on tumor immunology and cancer immunotherapy.” He has also served SITC as a member of Cancer Immunotherapy Fellowship Awards and Immune Biomarkers Task Force.
Dr. Bronte has been section editor for The Journal of Immunology, associate editor of Frontiers in Immunology and Frontiers in Oncology, consulting editor for Journal of Clinical Investigation and senior editor for Cancer Immunology Research and Cell Stress. He is the author of 124 articles published in peer-reviewed journals. His H-index is 66 with 22,613 citations. Dr. Bronte is a member of several cancer research associations and scientific societies, as well as a consultant/advisor for different companies, in Europe and U.S. Some of these companies are developing new drugs in the field of oncoimmunology based on the discoveries of Dr. Bronte.